argenx is rated Buy with a $1,000.50 price target. The market overreacts to the Sjögren's trial cancellation, ignoring commercial execution in myasthenia gravis and polyneuropathy that will drive $43.50 in 2027 EPS.
Key points
- $1,516 million in second-quarter product net sales grew 59.8% year-over-year, establishing a $6.06 billion commercial baseline.
- 32.6% operating margin in the latest quarter proves massive operating leverage as commercialization scales ahead of fixed research spending.
- 22.3% upside to our $1,000.50 price target emerges as the market overreacts to the discontinuation of the Sjögren's clinical trial.
The call
The market prices argenx at 18.6 times 2027 earnings, implying that commercial sales growth rapidly stalls near $6.5 billion following the Sjögren's trial termination. That assumes the entire long-term franchise value rested on rheumatology expansion, discounting established demand. It mistakes a single pipeline setback for an impairment of the core antibody franchise.
argenx quarterly product net sales ($M)- Reported product sales
- Estimated product sales
Company reports and analyst estimates. In USD millions.
We project product sales reach $8.65 billion in 2027 as generalized myasthenia gravis penetrates earlier lines and chronic inflammatory demyelinating polyneuropathy converts entrenched immunoglobulin users. Operating leverage expands margins toward 39%, generating $43.50 in diluted earnings per share. Trading at 23 times forward earnings, the shares deserve a $1,000.50 target.
Valuation
| Valuation driver | 2027 estimate |
|---|
| Product net sales | $8,650 million |
| Operating margin | 38.7% |
| Operating profit | $3,350 million |
| Net income | $2,762 million |
| Diluted shares outstanding | 63.5 million |
| Diluted EPS | $43.50 |
| Target P/E multiple | 23.0x |
| Price target | $1,000.50 |
A 23.0 times forward multiple matches prime commercial-stage biotechnology platforms compounding earnings above 30% with cash reserves exceeding $3 billion. Asymmetry favors buyers following an 18.7% one-month correction that wiped out $10 billion in value over a secondary indication.
Risks
- Entrenched immunoglobulin prescribing habits in chronic demyelinating polyneuropathy could slow conversion, visible in slowing quarterly US sequential net sales growth below 10%.
- Competitive neonatal Fc receptor therapies could prompt pricing pressure, detectable in gross-to-net discount widening in quarterly disclosures.
- Regulatory resistance to approval in immune-mediated necrotizing myopathy after dermatomyositis missed statistical significance, detectable in FDA pre-BLA meeting minutes.
What would change my mind
A persistent sequential slowdown in US myasthenia gravis treatment starts combined with failure of the multifocal motor neuropathy Phase 3 trial would force a downgrade.